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AbstrACt
Introduction Sarcopenia is a progressive loss in muscle 
mass, strength and function, the adverse consequences 
of which are severe, affecting quality of life and placing 
an increasing burden on social and healthcare systems. 
Vitamin D status is known to be associated with markers 
of sarcopenia, namely muscle mass, strength and function. 
Also, resistance exercise training (RET) is currently the 
only proven intervention to treat sarcopenia. However, 
very little data exist on the influence of combining the 
two interventions of vitamin D supplementation and 
resistance exercise training, although a recent systematic 
review provides tentative support for the current study’s 
hypothesis that the combined intervention may further 
improve musculoskeletal function above exercise training 
alone. The aim of the present study is to determine whether 
vitamin D3 supplementation is any more effective in 
improving musculoskeletal function when combined with 
RET compared with exercise training alone in older adults.
Methods and analysis This double- blinded randomised 
placebo- controlled trial will recruit a target of 127 eligible 
men and women aged ≥65 years living independently or 
in sheltered housing within the Birmingham area to two 
groups: (1) 6 months RET and placebo or (2) 6 months 
RET and 800 IU/d vitamin D3. Measures of muscle power 
(Nottingham Power Rig), body composition (dual energy 
X- ray absorptiometry), muscle function (short physical 
performance battery, timed up and go), falls and fractures 
as events will be assessed. Assessments will take 
place at baseline and postintervention, with intermittent 
monitoring of bone turnover, calcium and vitamin D. The 
primary outcome will be lower limb extensor power output. 
Analyses of within- group changes and between- group 
differences in outcome measures are planned.
Ethics and dissemination The EXVITD study has ethical 
approval granted by the Black Country National Health 
Service Research Ethics Committee (14/WM/1220). 
Results of this trial will be submitted for publication in 
peer- reviewed journals and presented at conferences. The 
study is being conducted according to the principles of the 
Declaration of Helsinki.
trial registration number
NCT02467153; Post- results.
IntroduCtIon
The UK has an ageing population; life expec-
tancy has increased rapidly in the previous two 
decades, with life expectancy at birth between 
2010 and 2012 reaching 82.72 for females and 
78.85 years for males.1 Importantly, healthy 
life expectancy is not keeping pace; adults 
over 65 years are expected to spend approx-
imately 7.9 years in poor health.2 Sarcopenia 
refers to the age- related loss of muscle mass, 
strength and function.3 Using the European 
Working Group on Sarcopenia in Older 
People criteria, the prevalence of sarcopenia 
has been reported to be from 1% to 33% in 
adults of mean age 59.2–85.8 years. The prev-
alence is higher in older adults in long term 
strengths and limitations of this study
 ► The present study is a randomised, double- blind, 
placebo- controlled trial, which is the appropriate de-
sign to assess the primary and secondary outcome 
measures.
 ► The resistance training aspect of the study uses 
body weight, ankle weights and physiotherapy 
bands, which present a feasible daily home or group 
exercise routine for older adults.
 ► The study assesses a large number of outcome 
measures relating to musculoskeletal health, includ-
ing dual energy X- ray absorptiometry, bone turnover 
markers, 25(OH)D and calcium monitoring and mus-
cle strength and function parameters.
 ► A limitation of the study is the lack of a precise and 
quantifiable measures of exertion and exercise pro-
gression/muscle loading.
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(eg, care home prevalence was 14%–33%) and acute care 
(hospital setting prevalence was 10%) settings.4 In the 
face of an increasing proportion of older adults and the 
dramatic increase in pressure on health and social care,5 
many are likely to suffer the adverse consequences of 
sarcopenia, namely impaired functional ability, increased 
frequency of falls and fractures, with attendant morbidity 
and mortality; a higher incidence of hospitalisations 
and longer length of hospital stay.6 Sarcopenia, there-
fore, represents a serious and increasing public health 
problem. The causes of sarcopenia are unclear, however, 
there are numerous factors associated aetiology.7–10
One such example is vitamin D deficiency; older adults 
are considered an ‘at risk group’, with prevalence rates 
of hypovitaminosis D reaching 89% in residential care.11 
Consequences of vitamin D deficiency include muscle 
weakness and an increased risk of falls and fractures.12 
While it is known that vitamin D is essential for calcium 
and phosphorous homoeostasis and bone health,12 we 
know relatively little about the direct effects of vitamin 
D on muscle mass and function in humans. The majority 
of evidence for an effect on muscle is based on animal 
models, which have reported increases in muscle protein 
synthesis in response to vitamin D supplementation but 
which may not mimic the human condition,13 14 and 
cross- sectional epidemiology15–17 which cannot establish 
causality.
One recent study of 100 community- dwelling older 
adults (mean age 69.9 years) with baseline serum 
25(OH)D concentrations <50 nmol/L receiving 800 IU 
D3 or a placebo daily for 12 months found that double 
leg press and grip strength were more improved and 
total and appendicular lean mass loss was smaller within 
the vitamin D group, although there were no significant 
between- group differences.18 Meta- analyses examining 
the effect of vitamin D supplementation on musculoskel-
etal parameters report conflicting evidence, although 
supplementation was shown to improve muscle strength, 
with effects more pronounced in older and vitamin D 
deficient participants.19 Another factor associated with 
sarcopenia is physical activity. Resistance exercise training 
(RET) is the most promising intervention for improving20 
and also reversing sarcopenia.21 It is the position of the 
Society on Sarcopenia, Cachexia and Wasting Disorders 
that RET should be implemented in the management of 
sarcopenia,22 since it is known to improve muscle mass, 
strength and function.21 23 24 Although and others have 
shown that even in very old adults (>75 years), RET 
improves muscle strength and functional outcomes, the 
hypertrophic ability of older muscle is blunted compared 
with younger adults.25 26 Therefore, in order to help older 
adults maintain good musculoskeletal health, interven-
tions to optimise responsiveness to physical activity are 
likely to be most effective if they are multimodal and 
include resistance exercise. One such example is the 
combination of RET with vitamin D supplementation.
Very few data exist that test the combined effects 
of vitamin D3 supplementation and RET on the 
musculoskeletal health of older adults, as highlighted 
by two recent systematic reviews.27 28 The first review 
included two studies, both of which found no additional 
effect of vitamin D on muscle mass or strength, although 
one study reported a further improvement in the timed 
up and go (TUG) test in participants supplemented with 
vitamin D.28 One further systematic review and meta- 
analysis identified a total of seven studies and concluded 
that vitamin D supplementation and exercise training 
significantly improved muscle strength within the lower 
limb in comparison with exercise training alone (0.98, 
95% CI 0.73 to 1.24, p<0.001).27 However, the limitations 
of the review serve to highlight the lack of knowledge 
within this area; only three studies were included in this 
meta- analysis, and the high weighting of one particular 
study meant that only tentative conclusions could be 
drawn.
Therefore, the principal aim of the EXVITD study is 
to determine whether vitamin D3 supplementation is 
more effective in improving musculoskeletal function 
when combined with RET compared with RET alone. We 
are focusing on the components of sarcopenia such as 
muscle mass, power and function rather than assessing 
the direct effects of the intervention on sarcopenic partic-
ipants since improvements made in these parameters will 
be beneficial for all older adults, not just those who are 
sarcopenic. The hypothesis is that the combined inter-
vention may further improve musculoskeletal function 
above exercise training alone.
The primary aim will be assessed as muscle power 
(Nottingham rig and Leonardo Mechanography, muscle 
function (short physical performance battery (SPPB), 
TUG) and body composition and bone mineral density 
(dual energy X- ray absorptiometry, DXA). Secondary 
objectives include: (1) determining the seasonal variation 
of 25(OH)D in a population of frailer older adults both 
free living and those living in supported housing; (2) 
Investigating the association between baseline 25(OH)D 
and physical activity measured using accelerometry and 
responsiveness to RET; (3) Determining between- group 
differences with respect to changes in falls as events and 
Quality of life (QoL); (4) Determining between- group 
differences with respect to changes in fractures as events; 
(5) Determining the influence of RET on serum inflam-
matory markers (eg, interleukin-6) and (6) Investigating 
the influence of RET on serum stress markers (cortisol, 
Dehydroepiandrosterone (DHEAS)).
MEthods
study design
The study protocol is presented in line with the Standard 
Protocol Items: Recommendations for Interventional 
Trials guidelines (see Research Checklist). The study start 
date was April 2016, with study completion anticipated in 
January 2020.The EXVITD study is a two- arm exploratory 
double- blinded randomised placebo- controlled trial. 127 
participants will be identified, recruited and randomised 
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Table 1 EXVITD study eligibility criteria*
Inclusion 
criteria
Aged ≥65 years
Ambulatory (with or without walking aids)
Living independently or within sheltered housing 
accommodation
Exclusion 
criteria
History of myocardial infarction within previous 2 
years
Cardiac illness: moderate/severe aortic stenosis, 
acute pericarditis, acute myocarditis, aneurysm, 
severe angina, clinically significant valvular 
disease, uncontrolled dysrhythmia, claudication 
within the previous 10 years; thrombophlebitis or 
pulmonary embolus within the previous 2 years
History of cerebrovascular disease 
(cerebrovascular accidentor transient ischaemic 
attack) within the previous 2 years
Acute febrile illness within the previous 3 months
Severe airflow obstruction; uncontrolled metabolic 
disease (eg, thyroid disease or cancer)
Significant emotional distress, psychotic illness or 
depression within the previous 2 years
Lower limb fracture sustained within the previous 
2 years/upper limb fracture within the previous 6 
months
Non- arthroscopic lower limb joint surgery within 
the previous 2 years
Any reason for loss of mobility for greater than 
1 week in the previous 2 months or greater than 2 
weeks in the previous 6 months
Resting systolic pressure >200 mm Hg or resting 
diastolic pressure >100 mm Hg
Poorly controlled atrial fibrillation; poor (chronic) 
pain control
Moderate/severe cognitive impairment (Mini- 
Mental State Examination score <23)
Vitamin D deficiency (serum 25(OH)D3 <30 nmol/L); 
current antiresorptive/anabolic treatment for 
osteoporosis
Treatment with bisphosphonates for osteoporosis 
in the past 2 years
Current use of glucocorticoids; known primary 
hyperparathyroidism
Renal impairment (stage 4 or 5)
*Based on previously published criteria of exercise studies with 
older adults.44
1:1 into two groups: (1) RET and 800 IU vitamin D3 
per day or, (2) RET and a daily placebo for 6 months. 
Eligibility will be assessed at screening, with all outcome 
measures to be collected at baseline and 6 months and 
venous blood sampling additionally assessed at months 1 
and 3.
The EXVITD study will take place within Birmingham, 
at both the University of Birmingham and the Wellcome 
Trust Clinical Research Facility (CRF) at the Queen Eliz-
abeth Hospital. Data collection began in July 2017 and 
collection/analysis is expected to be completed by 31 
December 2019.
study population
We aim to recruit 127 men and women aged ≥65 years, 
who are ambulatory (with/without aids) and live inde-
pendently or within sheltered housing accommodation in 
Birmingham, West Midlands, UK. We have selected this 
population as they are more susceptible to sarcopenia 
and subsequent functional deficits and therefore stand 
to benefit from interventions aimed to improve muscu-
loskeletal health. Eligibility criteria are summarised in 
table 1. Since confirmation of eligibility in this low- risk 
study does not require the interpretation of medical 
notes/history or a physical examination, the study chief 
investigator (CI) is suitably qualified to confirm eligibility. 
However, any queries about eligibility will be raised with 
the medical expert before a decision is taken.
recruitment
Recruitment strategies will be threefold and detailed 
below.
Primary care approach
We will work with the West Midlands Clinical Research 
Network who will assist with recruitment via primary care 
and help identify additional supported housing facilities 
under their aegis. Eligible participants from surrounding 
areas will be identified via an electronic practice- based 
search of registers using the criteria described in table 1. 
The general practitioner (GP) will review and exclude 
anyone they deem unsuitable for reasons other than 
those identified in the protocol (eg, already taking part 
in another study).
A patient approach letter will be sent to identified 
patients from the GP together with a participant infor-
mation sheet (PIS, see online supplementary file 1), reply 
form and FREEPOST envelope addressed to the study 
team. Alternatively, the research team can be contacted 
directly by phone or email. Patients not responding 
to the first invitation will receive one reminder after 3 
weeks, including an acknowledgement that the letter may 
be ignored by those that responded to the initial letter. 
When the study team receive a signed patient contact 
agreement consent form, they will contact the potential 
participant via telephone to discuss the study in more 
detail, go through the questionnaire responses and if 
eligible, obtain consent.
sheltered housing approach
Sheltered housing managers and head offices will be 
contacted directly, and where possible, study information 
will be presented at residents’ meetings, coffee mornings 
and on communal notice boards. Residents can contact 
the study team directly or through the housing manager. 
When a response is received, the participant will be 
contacted as detailed above.
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Table 2 Eligibility screening assessments
Informed 
consent
Face- to- face at participant’s home or at 
the University of Birmingham
General Health 
Questionnaire
1. Telephone call or at participant’s home or 
at the University of Birmingham
2. Answering ‘yes’ to any question outlined 
in the exclusion criteria shown in table 1
Mini- Mental State 
Exam
1. At participant’s home or at the University 
of Birmingham
2. A score <23
Venous blood 
draw to assess 
serum 25(OH)D 
status
1. At participant’s home or at the University 
of Birmingham
2. Serum 25(OH)D<30 nmol/L
Physical activity 
monitoring 
(accelerometry)
1. At participant’s home or at the University 
of Birmingham
2. A descriptive to be used during 
stratification
Independent living approach
We will recruit older adults living independently via 
several methods. Study information will be displayed 
at appropriate locations, for example, seniors’ groups, 
community centres and libraries. Additionally, advertise-
ment will be via appropriate and relevant websites, print 
media (eg, magazines, leaflets, newsletters) and social 
media. Members of the Birmingham 1000 Elders cohort 
managed by the University of Birmingham will also be 
recruited. Study information will be presented at seniors’ 
group meetings and direct contact to a member of the 
study team will be answered as detailed above.
Eligibility screening
The assessments completed during eligibility screening 
are documented in table 2, and will be conducted via one 
of following methods:
1. For participants identified via the primary care or in-
dependent living approach, the health questionnaire 
(see online supplementary file 2) will be conducted 
via telephone, with subsequent tests completed at the 
University of Birmingham.
2. For participants identified via the sheltered housing 
approach, all eligibility screening tests will be conduct-
ed within the participant’s own home, provided health 
and safety requirements for the blood draw are met. 
Should requirements not be satisfied, transport will 
be arranged for the participant and the visit will take 
place at the University of Birmingham.
Consent
It is the responsibility of the investigator to obtain 
written informed consent for each participant prior to 
performing any trial related procedure. A PIS will be 
provided to facilitate this process and the participant will 
be given at least 1 week to read the PIS and discuss partic-
ipation with others outside the research team. For partic-
ipants recruited via the primary care network approach, 
a signed patient contact agreement consent form will be 
received before any contact is made.
Investigators will ensure they adequately explain the 
aim, trial treatment, anticipated benefits and potential 
hazards, and the participant will be given the opportunity 
to ask questions. They will also stress that participation 
is voluntary and that the participant is free to refuse to 
take part/withdraw from the trial at any time without it 
affecting their future care. If interest in participation in 
the trial is confirmed, they will be asked to sign and date 
the consent form (see online supplementary file 3).
At each visit the participant’s willingness to continue 
in the trial will be ascertained. Throughout the trial the 
participant will have the opportunity to ask questions 
about the trial. Any new information that may be rele-
vant to the participant’s continued participation will be 
provided. Where new information becomes available 
which may affect the participants’ decision to continue, 
participants will be given time to consider and if happy 
to continue will be reconsented. Reconsent will be docu-
mented in the medical notes and the participant’s right 
to withdraw will remain. With the participant’s consent, 
their GP will be informed of their participation.
randomisation, allocation and blinding procedures
Participants will be randomised by a University Hospitals 
Birmingham statistician (PN) to one of two arms: (1) 
RET +800 IU vitamin D3 daily (intervention) or 2) RET 
+placebo daily for 6 months (control). Participants will be 
stratified on the basis of vitamin D status (high ≥50 nmol/L, 
low=30–50 nmol/L), physical activity (measured preran-
domisation using accelerometry, high ≥7000 steps per day, 
low <7000 steps per day) and sex. Randomisation will be 
computer generated using the random number function 
in Microsoft Excel with a mixture of block sizes of four 
and six. Allocation of participants into study group and 
labelling and allocation of the tablets into supplement 
bottles and adherence monitoring will be completed 
within the University of Birmingham, by an individual 
with no involvement in the study.
The study team and participants will be blinded to 
group allocation. Randomisation codes will be kept in 
individual sealed envelopes to avoid unblinding the 
whole cohort if an individual participant allocation is 
requested by the study team’s medical expert. In order 
to avoid assessor unblinding, all blood results will be 
viewed by the study team’s medical expert who may be 
unblinded as a consequence. Unblinding decisions will 
be taken by the study medical expert, in consultation 
with the CI. Arrangements for emergency unblinding 
if both the medical expert and CI are unavailable will 
be according to established UHB practice embedded 
within its governance structure. The CRF does not open 
24 hours a day, however, the CRF clinical manager has 
24 hours access to the relevant information. The study 
timeline schematic is shown as figure 1 in online supple-
mentary file 4.
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study intervention: intervention arm
Resistance exercise training
A rolling group exercise programme with a maximum 
of 12 participants per group and no more than 2 groups 
running concurrently will be established. Group 1 will 
run alone for 3 months to check for practical issues 
before completing the 6- month intervention. The exer-
cise training intervention will be delivered by the study 
team in partnership with a specialist exercise instructor 
who will deliver initial training, supervision and regular 
quality assessment. The specialist exercise instructor 
will provide a copy of their public, personal trainer and 
coaches liability Insurance certificate to the CI.
The evidence- based Peer Exercise Programme Promotes 
Independence (PEPPI) programme will be used within 
the EXVITD study and has been adapted by the specialist 
exercise instructor to suit a wider range of functional abil-
ities (ie, more standing exercises for higher functioning 
participants) with permission from the ageing and phys-
ical activity expert of the PEPPI programme William 
Evans.29 Balance and coordination exercises from the 
OTAGO programme30 will also be incorporated since it 
has been reported that a combination of RET and balance 
exercises were more effective at reducing the rate of falls 
than balance or function exercise alone.31 The specialist 
exercise instructor has over 10 years of experience of 
delivering these exercises to older adults across the range 
of functional abilities, including those with very limited 
mobility, within the community and population from 
which we will recruit. The programme has the support 
of experts in the field including Janet Lord, Professor 
of Immune Cell Biology and director of the Institute 
for Inflammation and Ageing at Birmingham University 
Medical School and a director of the Medical Research 
Council- Versus Arthritis Centre for Musculoskeletal 
Ageing Research. The programme has been approved by 
the Falls Prevention Lead nurse for University Hospitals 
Birmingham and has been utilised within the National 
Health Service (NHS), University of Birmingham, the 
Royal Voluntary Service, St Giles Hospice and Age UK. 
Move It Or Lose It! have the support of an advisory board 
of experts within the field (including JL, chartered phys-
iotherapists and the Head of Strategy and Development 
at the Royal Voluntary Service).
The EXVITD RET programme will follow the same 
format as the PEPPI programme including a dynamic 
warm- up and aerobic section with range of motion 
stretches (approximately 15 min), balance and coordina-
tion section (approximately 10 min), resistance training 
section (approximately 20–25 min) and a cool down with 
stretches (approximately 10–15 min). Each session will 
last for approximately 60 min, with two sessions per week 
for 6 months. The sessions will be tailored and progressed 
individually to a range of abilities within the target group. 
The warm- up and aerobic section and cool down will be 
performed to music. We will be using resistance bands 
(colours ranging from red to black) and ankle weights 
(participants can start without and can gradually progress 
to using 0.5, 0.75 and 1 kg ankle weights) during the 
strength/resistance section of the group sessions, with a 
focus on, although not exclusively, the lower body since 
this is our primary outcome measure. Types of resistance 
work are shown on the Move It Or Lose It website (https://
www. moveitorloseit. co. uk/ about- us/). As standard, all 
class attendees will complete a Physical Activity Readiness 
Questionnaire prior to beginning the intervention.
Attendance at group sessions will be monitored via a 
register, and participants will be asked to report any non- 
attendances to a member of the study team. Progression 
will be assessed via the 30 s sit to stand challenge, band 
colour/ankle weight used and repetitions of resistance 
exercises. Groups will run throughout the year to miti-
gate for seasonal variation in vitamin D status. Exercise 
sessions will be held in communal living spaces for partic-
ipants recruited via the sheltered housing route or within 
the Morris Club Centre, an NHS health, fitness and well- 
being centre located on the Queen Elizabeth Hospital 
campus, for participants recruited via the independent 
living or primary care approach. Prepayed transport to 
and from the exercise sessions will be offered to all partic-
ipants in order to remove a potential barrier to partic-
ipation and promote participant retention. During the 
study, participants will be asked to continue with their 
usual daily activities but not to start any additional phys-
ical activity or supplements; after the study is completed 
a book or DVD of the training exercises will be given to 
encourage continued physical activity as a lifestyle choice.
Vitamin D3 supplementation
In line with the current Institute Of Medicine32 and 
Royal Osteoporosis Society33 guidelines, the daily dose of 
vitamin D3 is 800 IU. This is below the UK Food Stan-
dards Agency publicly stated safe limit for daily vitamin 
D intake at 1000 IU,34 although this has been criticised 
as overly conservative.35 The Institute of Medicine set a 
Tolerable Upper Intake Level for vitamin D of 4000 IU 
per day32 and the European Food Safety Agency Panel 
on Dietetic Products, Nutrition and Allergies have set a 
no observed adverse effect level of 10 000 IU per day.36 
Additionally, hypercalcaemia, the hallmark of vitamin 
D intoxication, has only been consistently observed in 
anecdotal evidence when 25(OH)D concentrations are 
between 375–500 nmol/L.37 Therefore, assessment and 
monitoring of serum 25(OH)D and calcium will occur 
throughout the study although we do not anticipate any 
reason for early termination of the study.
Individual supplies of over the counter vitamin D 
supplements provided by IVC Brunel Healthcare will be 
given to participants in tablet form packed in pots; pots 
will contain a 4- week supply of supplements (28 tablets) 
and one 800 IU tablet is to be taken per day. Tablets will 
be stored at ambient temperature by the study team 
within the University of Birmingham, and distributed 
to participants every 4 weeks. Tablet manufacture will 
be undertaken by Brunel Healthcare in a Medicines 
and Healthcare products Regulatory Agency (MHRA) 
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Table 3 EXVITD study outcome measures
Time point
Enrolment
Trial period
Allocation Post- allocation Follow- up
−56 to −7 days
(Screening)
−7 to 0 days
(Baseline)
Month
1
Month
3
Month
6
+1 to +7 
days
Enrolment
  Informed consent* X
  Health questionnaire X
  MMSE X
  Venous blood sampling X X X X X X
  Blood pressure X X
  Physical activity monitoring 
(accelerometery)
X X
  Allocation X
Interventions
  Resistance exercise training   
  Vitamin D or placebo   
Outcome assessments
  Lower limb extensor power 
(Nottingham power rig)†
X X
  Body composition and BMD (DXA)‡ X X
  Chair rise (Leonardo force plates)‡ X X
  Functional ability (SPPB and TUG)‡ X X
  Falls as events† X X X X X X
  Fractures as events† X X X X X X
  Quality of life (SF-36)† X
  Musculoskeletal pain questionnaire† X X
  Food diary† X X
Food diary: see online supplementary file 6.
*Informed consent form will be signed during the screening visit and will be reconfirmed verbally at each following time point.
†Primary outcome measure.
‡Secondary outcome measures.
BMD, bone mineral density; DXA, dual energy X- ray absorptiometry; MMSE, Mini- Mental State Examination; SF-36, 36 item Short Form 
Survey; SPPB, short physical performance battery; TUG, timed up and go.
licensed facility, labelling and allocation of tablets into 
pots will take place within the University of Birmingham 
by an individual with no involvement in the study. Labels 
will contain the following information: number of tablets 
(28); dose (20 µg/800 IU); schedule and directions of use; 
storage information; date; participant ID; batch infor-
mation; trial name (EXVITD) and study team contact 
number. Compliance will be monitored by the return of 
used tablet pots, with gentle compliance reminders given 
to participants during the exercise sessions.
study intervention: control arm
Participants randomised to the control arm of the trial will 
receive the RET intervention alongside the intervention 
group and a daily placebo supplement distributed and to 
be taken in the same way as the vitamin D3 supplements.
outcome assessments
A list of scheduled outcome assessments is presented in 
table 3. Outcome measures will be assessed by the study 
team, with the exception of the DXA scan (performed by a 
radiographer). For the reliability and validity of outcome 
measures in older adults, see online supplementary file 5.
sample size calculation
We estimate n=114 participants will give 80% power at 
the 5% level (two- sided test) to detect an additional 19% 
improvement in the primary outcome measure (lower 
limb power output) above that expected as a result of RET 
alone (ie, 29%, assuming SD of 26% and 43% in the two 
groups). This represents a gain of over 10 ‘mobility years’ 
assuming an annual loss of power of 1.5%. This sample 
size also allows detection of a 1.0- point increase on the 
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SPPB score over and above an assumed 1.5- point increase 
due to exercise training alone. These calculations are 
based on a combination of our own pilot data and previ-
ously published data.25 38–40 Informed by our experience 
of exercise interventions with older adults and patient 
groups we have added 13 participants to cover an antici-
pated 10% drop- out rate, giving a total of n=127 partici-
pants to be recruited.
statistical analysis
All data will be entered into a database and analysed 
using IBM SPSS Statistics for Windows, V.25.0. Data anal-
ysis will be conducted on both an intention- to- treat and 
per- protocol basis. Normality will be assessed by visual 
inspection of Q- Q plots and the characteristics of partic-
ipants at baseline will be summarised using means and 
SD, medians and quartiles or counts and percentages, as 
appropriate. The comparison of primary interest is the 
difference at baseline and 6- month follow- up between 
the intervention and control groups. Appropriate log 
transformations will be applied prior to analysis of cova-
riance (ANCOVA) for primary and secondary outcome 
measures. Covariates applied to the analysis will include 
age, sex, physical activity and baseline serum 25(OH)D. 
All statistical tests conducted will be two sided with an 
alpha level of p=0.05 with missing data addressed using 
multiple imputation. There are no planned subgroup or 
interim analyses.
data collection, management and monitoring
All personal data will be handled and stored with the 
strictest confidence and in accordance with the Data 
Protection Act 2018. Personal details such as home 
address, name, date of birth and contact number will 
be provided by the participant in the signed participant 
contact agreement form or in person during an intro-
ductory meeting, with the purpose of future contact. 
Potential participants will be made aware that personal 
data collected during the study will be kept confidential 
and stored securely at the University of Birmingham in a 
locked cabinet accessible only to members of the study 
team. Additionally, participants will be aware that relevant 
sections of medical notes and data collected during the 
study may be looked at by responsible individuals from 
the University Hospitals Birmingham NHS Foundation 
Trust.
Once allocated to one of the study groups, participants 
will be assigned a unique personal identification code, 
which will be used from this point onwards to identify 
them in all documentation, correspondence between the 
participating sites and the case report form (see online 
supplementary file 7). In the case of specific issues and/
or queries from regulatory authorities, it will be necessary 
to have access to the complete trial records, provided that 
participant confidentiality is protected. Personal data will 
be kept for 10 years after the last data capture in line with 
University of Birmingham policy to allow for verification.
Missing data
Data reported on each case report form will be consis-
tent with the source data and any discrepancies will 
be explained. All missing and ambiguous data will be 
queried. Individual data sets will be checked by the CI 
at regular intervals and discrepancies highlighted and 
listed. These will be viewed and discussed by the trial 
management group.
storage and analysis of samples
In total, five blood samples (10 mL) will be taken from 
participants completing the study; time points are shown 
in table 3. The samples will be analysed at the Queen Eliz-
abeth clinical haematology laboratory (full blood count, 
blood biochemistry, liver and renal function, serum 
25(OH)D), the University of Birmingham Institute of 
Inflammation and Ageing (stress and inflammatory 
markers) under the supervision of a member of the study 
team and at the University of Liverpool (bone turnover 
markers) following a material transfer agreement. Blood 
to be analysed at the Queen Elizabeth hospital will be sent 
for processing immediately, bloods to be analysed by the 
University of Birmingham and Liverpool will be stored at 
the Wellcome Trust CRF at the Queen Elizabeth hospital 
at −80°C for analysis once data collection is complete. 
Collection, analysis, storage and destruction of residual 
blood samples will be according to local policy and stan-
dard operating procedures aligned to the University of 
Birmingham Quality Management System.
Monitoring and auditing
This is a low- risk single centre trial, and thus, the study 
team do not consider the support of a data monitoring 
committee to be necessary; however, monitoring of the 
study by the University of Birmingham Clinical Research 
Compliance Team, including access to source documents 
as requested, will be permitted. They will review at inter-
vals agreed with the CI.
Patient and public involvement
No patient was involved in the design of this study, 
although a trial steering committee will comprise the trial 
management group, one external senior academic, one 
representative from a Housing Trust and two older adults 
from the Birmingham 1000 Elders database.
All study team members have received necessary 
training and will conduct the study in accordance with 
Good Clinical Practice guidelines.
safety monitoring
Serious adverse events (SAEs), defined as any event that 
could be related to the study that caused injury or hospi-
talisation, will be reported to the CI and the CRF’s clinical 
manager for review within 24 hours after first becoming 
aware of the event. All SAEs will be reviewed formally 
every 2 weeks during CRF operations meetings, which 
include representation from the trust research, develop-
ment and innovation office.
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Amendment
Should the authors wish to make any substantial amend-
ments to the REC application or supporting documenta-
tion, a notice of amendment will be submitted for REC 
consideration.
dissemination policy
Results of this trial will be submitted for publication in 
peer- reviewed journals. The manuscript will be prepared 
by the study team led by the CI. Authors will acknowledge 
that the trial was performed with the support of the Royal 
Osteoporosis Society. Participants will be contacted and 
provided with a copy of the publication.
dIsCussIon
Although exercise is currently the only proven mech-
anism to improve the symptoms of sarcopenia,41 the 
anabolic response to RET is blunted in older compared 
with younger adults25 26 and strategies to potentially over-
come this effect are lacking. A recent systematic review 
highlighted the lack of data in this area27 and provided 
tentative support for the combined intervention of 
vitamin D and RET.27 Very few studies to date have been 
appropriately designed to test the combined effects of 
vitamin D and exercise in older adults, and of the studies 
which have, poor exercise compliance42 and small sample 
sizes have been reported,43 limiting interpretation of the 
data.
Therefore, the EXVITD study aims to address these 
issues and bridge the gap in knowledge regarding the 
potential enhancement of the effects of RET by vitamin 
D supplementation. A sample size of n=127 represents 
a substantial addition to the current data and as the 
study team will be delivering the intervention (both the 
supplements and the RET sessions), adherence will be 
monitored closely and encouraged in person. A finding 
that RET and vitamin D supplementation is effective 
compared with RET alone will support the develop-
ment of future multimodal interventions to maintain 
bone and muscle health in old age and pave the way for 
further mechanistic and intervention studies examining 
the effects of RET/vitamin D in conjunction with other 
promising anabolic agents.
The strengths of this study include the design; a 
randomised double- blinded placebo- controlled trial is 
the most appropriate methodology to use to assess the 
primary and secondary outcomes. A range of outcome 
measures will provide a wealth of information regarding 
the musculoskeletal health of the participants. Addition-
ally, the present study aims to recruit older men and 
women, meaning that the results of the trial will be gener-
alisable with respect to sex.
One limitation of the study is the lack of a precise and 
quantifiable measure of exertion, exercise progression 
or muscle loading. Exertion will not be assessed in the 
present study; the use of objective measures such as heart 
rate monitors or rate of perceived exertion scales were 
rejected due to additional participant burden. Exercise 
progression and muscle loading would be more objec-
tively measured if gym- based resistance equipment were to 
be employed, however, the benefit of using body weight, 
ankle weights and physiotherapy bands is that these 
equipment will be more familiar and readily adapted to 
daily practice, so that new- found exercise habits may be 
maintained following the close of the study. Additionally, 
previous studies have emphasised benefit of vitamin D 
supplementation in deficient participants19; since vitamin 
D deficiency is an exclusion criterion, we may be less likely 
to observe meaningful clinical effects of supplementation 
in our vitamin D insufficient or replete participants.
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